Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer | Zendy

Pierre Bohanes | Zendy; D. Courvoisier | Zendy; TV Perneger | Zendy; Philippe Morel | Zendy; Olivier Huber | Zendy; AD Roth | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer

Author(s) -

Pierre Bohanes,

D. Courvoisier,

TV Perneger,

Philippe Morel,

Olivier Huber,

AD Roth

Publication year - 2011

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2011.13249

Subject(s) - medicine , hazard ratio , chemotherapy , proportional hazards model , cancer , oncology , univariate analysis , confidence interval , survival analysis , gastroenterology , multivariate analysis

There are very limited data suggesting a benefit for second-line chemotherapy in advanced gastric cancer. Therefore, the number of patients who receive further treatment after failure of first-line chemotherapy varies considerably, ranging from 14% to 75%. In the absence of a demonstrated survival benefit of second-line chemotherapy, appropriate selection of patients based on survival predictors is essential. However, no clinico-pathologic parameters are currently widely adopted in clinical practice. We looked exclusively at Caucasian patients with metastatic gastric cancer treated with second-line chemotherapy to see if we could establish prognostic factors for survival

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research